Pediatric Dermatology News

With Kim Kardashian speaking out about her son’s experience with vitiligo, Healio Dermatology sat with an expert to discuss the condition in the adult and pediatric populations.

Healio has compiled July’s most-read news in dermatology.

The FDA has approved Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged 6 years and older, Arcutis announced in a press release.

Clascoterone cream 1% caused mild, reversible hypothalamic-pituitary-adrenal axis suppression under maximum-use exposure in patients with acne vulgaris, according to a study.

Dupilumab treatment was associated with the reduced risk for atopic march progression in pediatric and adolescent patients with atopic dermatitis, according to a study.

Healio has compiled June’s most-read news in dermatology.

Topical tapinarof cream showed significant improvement of moderate to severe atopic dermatitis while being well tolerated by adults and children down to age 2 years, according to two phase 3 clinical trials.

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

The NIH has awarded Emma Guttman-Yassky, MD, PhD, a $6.6 million grant to investigate dupilumab as a treatment for children with alopecia areata, Mount Sinai announced in a press release.

Initiating infantile hemangioma treatment with propranolol 2 mg/kg per day did not yield more adverse events than 1 mg/kg per day, according to a study.